Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

Uchino, Junichi; Hirano, Ryosuke; Tashiro, Naoki; Yoshida, Yūji; Ushijima, Shinichiro; Matsumoto, Takemasa; Ohta, Keiichi; Nakatomi, Keita; Takayama, K.; Fujita, Masaki; Nakanishi, Yoichi; Watanabe, Kentaro

doi:10.7314/apjcp.2012.13.8.4187

Cited by 9 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the doctors and nurses should increase the knowledge of CINV first by starting some small sample studies. For example, a retrospective study by Japanese scholars (Uchino et al, 2012) revealed that effective antiemetic regimen showed signigicantly higher in food intake rate, completion rate of planned chemotherapy and complete suppression rate of nausea in advanced or recurrent lung cancer patients receiving moderately emetogenic chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Wang

Yang²,

Zhang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Wang

Yang²,

Zhang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…In clinical trials and in practice, prolongation of survival time appears to have been recorded in NSCLC patients in recent years, which may have been due to the appearance of more effective and less toxic drugs (17), molecular targeting agents (18)(19)(20)(21)(22) and the improvement of supportive therapy, such as G-CSF (23) and antiemetic drugs (24). In the present study, the survival of all consecutive NSCLC patients in daily practice was evaluated, therefore, the study included ʻunfitʼ patients, who are usually excluded from clinical trials.…”

Section: Recently Mandrekar Et Almentioning

confidence: 99%

Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the similar survival benefits of a good response [complete response or partial response (CR/PR)] and stable disease (SD) to chemotherapy in non-small cell lung cancer (NSCLC) patients in clinical practice. All 322 patients who were treated between 1999 and 2012 with first-line platinum-based chemotherapy were retrospectively analyzed. Tumor responses were classified according to the response evaluation criteria for solid tumors. A total of 67 (20.8%) patients experienced CR/PR and 165 (51.2%) achieved SD. There was no difference in progression-free survival between the patients with CR/PR and those with SD (P= 0.347). There was also no difference between the two groups with regard to overall survival time (P= 0.878). In multivariate analysis, disease-control (more than SD) was one of the favorable prognostic factors. In clinical practice, a survival benefit would be provided not only for the patients who have good response, but also for those with SD. IntroductionThe incidence and mortality rates of lung cancer have increased globally during the last few decades (1,2). The majority of cases of lung cancer diagnosed were non-small cell lung cancer (NSCLC), and ~40% of patients with NSCLC are affected by advanced diseases (3). For patients with advanced NSCLC with a good performance status, systemic chemotherapy is the standard therapy at present. The first-line treatment for such patients is platinum-based chemotherapy, which improves symptom control, quality of life and survival as compared with best supportive care (4). A good response [complete response or partial response (CR/PR)] to chemotherapy has typically been equated with the clinical benefit of increased survival (5), but only 20-30% of patients achieve a good response in previous clinical trials, while 40-50% maintain a stable disease (SD) status (6-8). Certain previous studies reported that an initial good response and stable disease indicate similar survival benefits for chemotherapeutical patients with advanced NSCLC (9,10). The present retrospective study was undertaken to evaluate the similar survival benefits of a good response and stable disease to platinum-based chemotherapy in previously untreated NSCLC patients. Patients and methodsPatients. The patients enrolled in the present study were those consecutively diagnosed with NSCLC and treated with platinum-based chemotherapy as first-line treatment at the University of Tsukuba Hospital and Tsukuba Medical Center Hospital (both Tsukuba, Ibaraki, Japan) between January 1999 and December 2012. All the patients were histologically/cytologically confirmed as presenting with NSCLC and unresectable advanced disease. The histopathological diagnosis was defined by the World Health Organization classification (11), and patients were staged according to the Union for International Cancer Control tumor-node-metastasis system (12). Treatment and response.Enrolled patients received at least one cycle of cisplatin-or carboplatin-based chemotherapy. The clinical, ...

show abstract

“…However, the primary regimen often has to be adjusted or even discontinued due to adverse events, with the chemotherapy-induced nausea and vomiting (CINV) being the most common one, which not only greatly increases the economic burden (Keat and Ghani, 2013) but also produces dehydration, electrolyte disturbance, sub-nutrition, anorexia, weight loss, hypodynamia, sleep deficit, esophageal laceration, and massive hemorrhage, which seriously reduce patients' quality of life (QoL) and are even life-threatening. These limitations hamper the progress of chemotherapy (Hassan and Yusoff, 2010;Uchino et al, 2012;Janelsins et al, 2013). The National Comprehensive Cancer Network (NCCN) and Multinational association of supportive care in cancer (MASCC) have formulated and revised the CINV antiemetic guidelines several times (Roila et al, 2010).…”

Section: Olanzapine For Preventing Nausea and Vomiting Induced By Modmentioning

confidence: 99%

“…Shi-Yong Wang 1 *, Zhen-Jun Yang 2 , Lu Zhang 1 chemotherapy remains a major therapeutic approach to improve cancer prognosis and cure (Hassan and Yusoff, 2010;Uchino et al, 2012;Janelsins et al, 2013;NCCN., 2014). However, the primary regimen often has to be adjusted or even discontinued due to adverse events, with the chemotherapy-induced nausea and vomiting (CINV) being the most common one, which not only greatly increases the economic burden (Keat and Ghani, 2013) but also produces dehydration, electrolyte disturbance, sub-nutrition, anorexia, weight loss, hypodynamia, sleep deficit, esophageal laceration, and massive hemorrhage, which seriously reduce patients' quality of life (QoL) and are even life-threatening.…”

Section: Olanzapine For Preventing Nausea and Vomiting Induced By Modmentioning

confidence: 99%

Olanzapine for Preventing Nausea and Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Wang

Yang²,

Zhang³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Nausea and vomiting are common adverse events in chemotherapy. In spite of the serious effects on the quality of life and further treatment, they remain overlooked by physicians, and no standard treatment has been developed. Neurokinin-1 (NK-1) receptor antagonists and palonosetron are the major agents in the standard regimen for treating moderately and highly emetogenic chemotherapy-induced nausea and vomiting (CINV). However, NK-1 receptor antagonists first became commercially available at the end of 2013 and palonosetron has not been extensively applied in China. Olanzapine was recommended as a therapy for moderate and severe CINV in antiemesis-clinical practice guidelines in oncology in 2014 for the first time. It is an atypical antipsychotic agent, which can block multiple receptors on neurotransmitters. During more than 10 years, olanzapine has demonstrated significant effects in preventing CINV and treating breakthrough and refractor CINV, which was observed in case reports, precise retrospective studies, and phase Ⅰ, Ⅱ and Ⅲ clinical trials, with no grade 3 to 4 adverse events. In particular, it is superior to aprepitant and dexamethasone in delayed nausea and vomiting. Therefore, this compound is worthy of further investigation.

show abstract

Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

Cited by 9 publications

References 24 publications

Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer

Olanzapine for Preventing Nausea and Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

Contact Info

Product

Resources

About